DOI: 10.1055/s-00000077

Seminars in Thrombosis and Hemostasis

Issue 02 · Volume 23 · April 1997 DOI: 10.1055/s-002-7327

  • 97
    Mammen, Eberhard F.:

    Preface

  • 99
    Malsch, Reinhard; Guerrini, Marco; Berti, Carlo; Naggi, Annamaria; Torri, Giangiacomo; Casu, Benito; Harenberg, Job:

    Synthesis and Biological Effects of N-Alkylamine-Labeled Low-Molecular-Mass Dermatan Sulfate

  • 109
    Piazolo, Lukas; Harenberg, Job; Malsch, Reinhard; Hüttner, Franz G.; Heene, Dieter L.:

    Comparison of the Pharmacodynamic and Pharmacokinetic Profiles of Two Low-Molecular-Mass Heparins in Rats

  • 119
    Jeske, Walter; Fareed, Jawed; Eschenfelder, Volker; Iqbal, Omer; Hoppensteadt, Debra; Ahsan, Ahmad:

    Biochemical and Pharmacologic Characteristics of Reviparin, a Low-Molecular-Mass Heparin

  • 129
    Cella, Giuseppe; Vettor, Roberto; Sbarai, Alessandra; Rossi, Edoardo; Rampin, Ernesto; Macor, Cinzia; Mussap, Michele; Plebani, Mario; Luzzatto, Guido; Girolami, Antonio:

    Endothelial Cell-Associated Tissue Factor Pathway Inhibitor (TFPI) Antigen in Severe Nondiabetic Obese Patients: Effect of Hyperinsulinemia

  • 135
    Pepe, Guglielmina; Giusti, Betti; Attanasio, Monica; Gori, Anna Maria; Comeglio, Paolo; Martini, Francesca; Gensini, Gianfranco; Abbate, Rosanna; Neri Serneri, Gian Gastone:

    Tissue Factor and Plasminogen Activator Inhibitor Type 2 Expression in Human Stimulated Monocytes is Inhibited by Heparin

  • 143
    Agnelli, Giancarlo; Sonaglia, Francesco:

    Recombinant Hirudin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip Surgery

  • 149
    Bergqvist, David:

    Prolonged Prophylaxis in Postoperative Medicine

  • 155
    Turpie, Alexander G. G.:

    Prophylaxis of Venous Thromboembolism in Stroke Patients

  • 159
    Engelberg, Hyman:

    Evidence That Endogenous Heparin Activity Deficiency may be an Important Factor in Atherogenesis

  • 167
    Harenberg, Job; Huhle, Günter; Piazolo, Lukas; Giese, Christina; Heene, Dieter L.:

    Long-Term Anticoagulation of Outpatients with Adverse Events to Oral Anticoagulants Using Low-Molecular-Weight Heparin

  • 173
    Valentine, Karen A.; Hull, Russell D.; Pineo, Graham F.:

    Low-Molecular-Weight Heparin Therapy and Mortality

  • 179
    Breddin, Hans Klaus:

    Treatment of Deep Vein Thrombosis: Is Thrombosis Regression a Desirable Endpoint?

  • 185
    Prandoni, Paolo; Lensing, Anthonie W. A.; Prins, Martin R.:

    The Natural History of Deep-Vein Thrombosis

  • 189
    Harenberg, Job; Huhle, Günter; Piazolo, Lukas; Wang, Lianchun U.; Heene, Dieter L.:

    Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Type II

  • 197
    Lewis, Bruce E.; Walenga, Jeanine M.; Wallis, Diane E.:

    Anticoagulation with Novastan® (Argatroban) in Patients with Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis Syndrome

  • 203
    Baumann, Hanno; Mueller, Udo; Keller, Ruprecht:

    Which Glycosaminoglycans Are Suitable for Antithrombogenic or Athrombogenic Coatings of Biomaterials? Part I: Basic Concepts of Immobilized GAGs on Partially Cationized Cellulose Membrane

  • 215
    Baumann, Hanno; Keller, Ruprecht:

    Which Glycosaminoglycans Are Suitable for Antithrombogenic or Athrombogenic Coatings of Biomaterials? Part II: Covalently Immobilized Endothelial Cell Surface Heparan Sulfate (ESHS) and Heparin (HE) on Synthetic Polymers and Results of Animal Experiments

  • 225
    Beijering, Rolinda J. R.; Cate, Hugo Ten; Nurmohamed, Michael T.; Ten Cate, Jan Wouter:

    Anticoagulants and Extracorporeal Circuits